BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Erfonrilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Erfonrilimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05985707-2240@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Erfonrilimab: Phase 2 readout est. (NCT05985707)
DESCRIPTION:Erfonrilimab\, phase 2.\nStudy: KN026 Plus Chemotherapy ± KN-0
 46 in HER2 Positive Colorectal Cancer and Biliary Carcinoma\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/erfonrilimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05985707
URL:https://assetmemo.bio/drug/erfonrilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099821-2240@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Erfonrilimab: Phase 2 readout est. (NCT06099821)
DESCRIPTION:Erfonrilimab\, phase 2.\nStudy: KN046 Plus Regorafenib or Apati
 nib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/erfonrilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06099821
URL:https://assetmemo.bio/drug/erfonrilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
